Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

The Burden of Cardiovascular Disease Risk Factors in the Middle East: A Systematic Review and Meta-Analysis Focusing on Primary Prevention

Author(s): Akshaya Srikanth Bhagavathula*, Abdullah Shehab, Anhar Ullah and Jamal Rahmani

Volume 19, Issue 4, 2021

Published on: 11 June, 2020

Page: [379 - 389] Pages: 11

DOI: 10.2174/1573406416666200611104143

Price: $65

Abstract

Background: The increasing incidence of cardiovascular disease (CVD) threatens the Middle Eastern population. Several epidemiological studies have assessed CVD and its risk factors in terms of the primary prevention of CVD in the Middle East. Therefore, summarizing the information from these studies is essential.

Aim: We conducted a systematic review to assess the prevalence of CVD and its major risk factors among Middle Eastern adults based on the literature published between January 1, 2012, and December 31, 2018, and carried out a meta-analysis.

Methods: We searched electronic databases such as PubMed/Medline, ScienceDirect, Embase and Google Scholar to identify literature published from January 1, 2012, to December 31, 2018. All the original articles that investigated the prevalence of CVD and reported at least one of the following factors were included: hypertension, diabetes, dyslipidaemia, smoking and family history of CVD. To summarize CVD prevalence, we performed a random-effects meta-analysis.

Results: A total of 41 potentially relevant articles were included, and 32 were included in the metaanalysis (n=191,979). The overall prevalence of CVD was 10.1% (95% confidence interval (CI): 7.1- 14.3%, p<0.001) in the Middle East. A high prevalence of CVD risk factors, such as dyslipidaemia (43.3%; 95% CI: 21.5-68%), hypertension (26.2%; 95% CI: 19.6-34%) and diabetes (16%; 95% CI: 9.9- 24.8%), was observed. The prevalence rates of other risk factors, such as smoking (12.4%; 95% CI: 7.7- 19.4%) and family history of CVD (18.7%; 95% CI: 15.4-22.5%), were also high.

Conclusion: The prevalence of CVD is high (10.1%) in the Middle East. The burden of dyslipidaemia (43.3%) in this region is twice as high as that of hypertension (26.2%) and diabetes mellitus (16%). Multifaceted interventions are urgently needed for the primary prevention of CVD in this region.

Keywords: Cardiovascular disease, hypertension, diabetes, dyslipidaemia, prevalence, Middle East.

« Previous Next »
Graphical Abstract

[1]
Thomas H, Diamond J, Vieco A, et al. Global atlas of cardiovascular disease 2000-2016: the path to prevention and control. Glob Heart 2018; 13(3): 143-63.
[http://dx.doi.org/10.1016/j.gheart.2018.09.511] [PMID: 30301680]
[2]
Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 2017; 70(1): 1-25.
[http://dx.doi.org/10.1016/j.jacc.2017.04.052] [PMID: 28527533]
[3]
Al-Kindi S, Al-Juhaishi T, Haddad F, Taheri S, Abi Khalil C. Cardiovascular disease research activity in the Middle East: a bibliometric analysis. Ther Adv Cardiovasc Dis 2015; 9(3): 70-6.
[http://dx.doi.org/10.1177/1753944715578585] [PMID: 25801472]
[4]
Almahmeed W, Arnaout MS, Chettaoui R, et al. Coronary artery disease in Africa and the Middle East. Ther Clin Risk Manag 2012; 8: 65-72.
[http://dx.doi.org/10.2147/TCRM.S26414] [PMID: 22368447]
[5]
Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937-52.
[http://dx.doi.org/10.1016/S0140-6736(04)17018-9] [PMID: 15364185]
[6]
Aljefree N, Ahmed F. Prevalence of cardiovascular disease and associated risk factors among adult population in the Gulf region: a systematic review. Adv Public Health 2015; 2015235101
[http://dx.doi.org/10.1155/2015/235101]
[7]
World Health Organization Cardiovascular Disease Factsheet 2015.http://www.who.int/mediacentre/factsheets/fs317/en/2019
[8]
World Health Organization Noncommunicable diseases country profiles 2014.
[9]
Motlagh B, O’Donnell M, Yusuf S. Prevalence of cardiovascular risk factors in the Middle East: a systematic review. Eur J Cardiovasc Prev Rehabil 2009; 16(3): 268-80.
[http://dx.doi.org/10.1097/HJR.0b013e328322ca1b] [PMID: 19398913]
[10]
Shara NM. Cardiovascular disease in Middle Eastern women. Nutr Metab Cardiovasc Dis 2010; 20(6): 412-8.
[http://dx.doi.org/10.1016/j.numecd.2010.01.013] [PMID: 20554171]
[11]
Alshaikh MK, Filippidis FT, Al-Omar HA, Rawaf S, Majeed A, Salmasi AM. The ticking time bomb in lifestyle-related diseases among women in the Gulf Cooperation Council countries; review of systematic reviews. BMC Public Health 2017; 17(1): 536.
[http://dx.doi.org/10.1186/s12889-017-4331-7] [PMID: 28578688]
[12]
Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res 2016; 118(11): 1752-70.
[http://dx.doi.org/10.1161/CIRCRESAHA.115.306883] [PMID: 27230640]
[13]
Behrouz R, Powers CJ. Epidemiology of classical risk factors in stroke patients in the Middle East. Eur J Neurol 2016; 23(2): 262-9.
[http://dx.doi.org/10.1111/ene.12742] [PMID: 26041584]
[14]
Traina MI, Almahmeed W, Edris A, Murat Tuzcu E. Coronary heart disease in the Middle East and North Africa: current status and future goals. Curr Atheroscler Rep 2017; 19(5): 24.
[http://dx.doi.org/10.1007/s11883-017-0659-9] [PMID: 28378303]
[15]
Donnelly TT, Al Suwaidi JM, Al-Qahtani A, et al. Depression in cardiovascular patients in Middle Eastern populations: a literature review. J Immigr Minor Health 2015; 17(4): 1259-76.
[http://dx.doi.org/10.1007/s10903-014-0052-5] [PMID: 24923859]
[16]
World Health Organization Prevention of cardiovascular disease. World Health Organization 2007.
[17]
Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151(4): 264-9.
[http://dx.doi.org/10.7326/0003-4819-151-4-200908180-00135] [PMID: 19622511]
[18]
Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag 2014; 3(3): 123-8.
[http://dx.doi.org/10.15171/ijhpm.2014.71] [PMID: 25197676]
[19]
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61(4): 344-9.
[http://dx.doi.org/10.1016/j.jclinepi.2007.11.008] [PMID: 18313558]
[20]
Haidich AB. Meta-analysis in medical research. Hippokratia 2010; 14(Suppl. 1): 29-37.
[PMID: 21487488]
[21]
Guddat C, Grouven U, Bender R, Skipka G. A note on the graphical presentation of prediction intervals in random-effects meta-analyses. Syst Rev 2012; 1(1): 34.
[http://dx.doi.org/10.1186/2046-4053-1-34] [PMID: 22839660]
[22]
Alrawahi AH, Lee P, Al-Anqoudi ZAM, et al. Cardiovascular risk prediction model for Omanis with type 2 diabetes. Diabetes Metab Syndr 2018; 12(2): 105-10.
[http://dx.doi.org/10.1016/j.dsx.2017.09.012] [PMID: 28986031]
[23]
Ramezankhani A, Azizi F, Hadaegh F, Momenan AA. Diabetes and number of years of life lost with and without cardiovascular disease: a multi-state homogeneous semi-Markov model. Acta Diabetol 2018; 55(3): 253-62.
[http://dx.doi.org/10.1007/s00592-017-1083-x] [PMID: 29299678]
[24]
Mirzaei B, Abdi H, Serahati S, et al. Cardiovascular risk in different obesity phenotypes over a decade follow-up: Tehran Lipid and Glucose Study. Atherosclerosis 2017; 258: 65-71.
[http://dx.doi.org/10.1016/j.atherosclerosis.2017.02.002] [PMID: 28213199]
[25]
Harari G, Green MS, Magid A, Zelber-Sagi S. Usefulness of non–high-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men in 22-year follow-Up. Am J Cardiol 2017; 119(8): 1193-8.
[http://dx.doi.org/10.1016/j.amjcard.2017.01.008] [PMID: 28267961]
[26]
Hajebrahimi MA, Akbarpour S, Eslami A, Azizi F, Hadaegh F. Different combinations of glucose tolerance and blood pressure status and incident cardiovascular disease and all-cause mortality events. J Hum Hypertens 2017; 31(11): 744-9.
[http://dx.doi.org/10.1038/jhh.2017.49] [PMID: 28748918]
[27]
Raee MR, Nargesi AA, Heidari B, et al. All-cause and cardiovascular mortality following treatment with metformin or glyburide in patients with type 2 diabetes mellitus. Arch Iran Med 2017; 20(3): 141-6.
[PMID: 28287807]
[28]
Hashemi Madani N, Ismail-Beigi F, Khamseh ME, Malek M, Ebrahimi Valojerdi A. Predictive and explanatory factors of cardiovascular disease in people with adequately controlled type 2 diabetes. Eur J Prev Cardiol 2017; 24(11): 1181-9.
[http://dx.doi.org/10.1177/2047487317707293] [PMID: 28447480]
[29]
Ramezankhani A, Azizi F, Hadaegh F, Eskandari F. Sex-specific clustering of metabolic risk factors and their association with incident cardiovascular diseases: A population-based prospective study. Atherosclerosis 2017; 263: 249-56.
[http://dx.doi.org/10.1016/j.atherosclerosis.2017.06.921] [PMID: 28683364]
[30]
Riyahi-Alam S, Derakhshan A, Mansournia MA, et al. Blood pressure and cardiovascular morbidity risk in type 2 diabetes with hypertension over a decade of follow-up: evidence for J-shaped phenomenon. J Hum Hypertens 2017; 31(6): 415-21.
[http://dx.doi.org/10.1038/jhh.2016.94] [PMID: 28124685]
[31]
Farhat A, Al-Hajje A, Rachidi S, et al. Risk factors and quality of life of dyslipidemic patients in Lebanon: A cross-sectional study. J Epidemiol Glob Health 2016; 6(4): 315-23.
[http://dx.doi.org/10.1016/j.jegh.2016.10.001] [PMID: 27842211]
[32]
Eslami A, Mozaffary A, Derakhshan A, Azizi F, Khalili D, Hadaegh F. Sex-specific incidence rates and risk factors of premature cardiovascular disease. A long term follow up of the Tehran Lipid and Glucose Study. Int J Cardiol 2017; 227: 826-32.
[http://dx.doi.org/10.1016/j.ijcard.2016.10.037] [PMID: 27829526]
[33]
Namazi Shabestari A, Asadi M, Jouyandeh Z, Qorbani M, Kelishadi R. Association of lipid accumulation product with cardio-metabolic risk factors in postmenopausal women. Acta Med Iran 2016; 54(6): 370-5.
[PMID: 27306343]
[34]
Al-Zakwani I, Al-Mahmeed W, Arafah M, et al. Control of risk factors for cardiovascular disease among multinational patient population in the Arabian Gulf. Curr Vasc Pharmacol 2016; 14(4): 374-81.
[http://dx.doi.org/10.2174/1570161113666151026115921] [PMID: 26496982]
[35]
Hadaegh F, Derakhshan A, Mozaffary A, Hasheminia M, Khalili D, Azizi F. Twelve-year cardiovascular and mortality risk in relation to smoking habits in type 2 diabetic and non-diabetic men: Tehran Lipid and Glucose Study. PLoS One 2016; 11(3)e0149780
[http://dx.doi.org/10.1371/journal.pone.0149780] [PMID: 26930192]
[36]
Ebrahimi H, Emamian MH, Hashemi H, Fotouhi A. Dyslipidemia and its risk factors among urban middle-aged Iranians: A population-based study. Diabetes Metab Syndr 2016; 10(3): 149-56.
[http://dx.doi.org/10.1016/j.dsx.2016.01.009] [PMID: 27033172]
[37]
Tabrizi JS, Sadeghi-Bazargani H, Farahbakhsh M, Nikniaz L, Nikniaz Z. Prevalence and associated factors of prehypertension and hypertension in Iranian population: The lifestyle promotion project (LPP). PLoS One 2016; 11(10)e0165264
[http://dx.doi.org/10.1371/journal.pone.0165264] [PMID: 27783691]
[38]
Alkaabi J, Gariballa S, Sharma C, et al. Inflammatory markers and cardiovascular risks among overweight-obese Emirati women. BMC Res Notes 2016; 9: 355.
[http://dx.doi.org/10.1186/s13104-016-2160-x] [PMID: 27440160]
[39]
Sardarinia M, Akbarpour S, Lotfaliany M, et al. Risk factors for incidence of cardiovascular diseases and all-cause mortality in a Middle Eastern population over a decade follow-up: Tehran lipid and glucose study. PLoS One 2016; 11(12)e0167623
[http://dx.doi.org/10.1371/journal.pone.0167623] [PMID: 27930696]
[40]
Farvid MS, Malekshah AF, Pourshams A, et al. Dietary protein sources and all-cause and cause-specific mortality: The Golestan cohort study in Iran. Am J Prev Med 2017; 52(2): 237-48.
[http://dx.doi.org/10.1016/j.amepre.2016.10.041] [PMID: 28109460]
[41]
Hariri N, Darafshi Ghahroudi S, Nasseri E, Bondarianzadeh D, Houshyar-Rad A, Zayeri F. Evaluation of the alternative healthy eating index as a predictor of 10-year cardiovascular disease risk in a group of Iranian employees. J Hum Nutr Diet 2017; 30(4): 499-505.
[http://dx.doi.org/10.1111/jhn.12416] [PMID: 27726209]
[42]
Perelshtein Brezinov O, Kivity S, Segev S, et al. Gender-related cardiovascular risk in healthy middle-aged adults. Am J Cardiol 2016; 118(11): 1669-73.
[http://dx.doi.org/10.1016/j.amjcard.2016.08.045] [PMID: 27737731]
[43]
Bahijri SM, Jambi HA, Al Raddadi RM, Ferns G, Tuomilehto J. The prevalence of diabetes and prediabetes in the adult population of Jeddah, Saudi Arabia-a community-based survey. PLoS One 2016; 11(4)e0152559
[http://dx.doi.org/10.1371/journal.pone.0152559] [PMID: 27035920]
[44]
Alzeidan R, Rabiee F, Mandil A, Hersi A, Fayed A. Non-communicable disease risk factors among employees and their families of a Saudi University: an epidemiological Study. PLoS One 2016; 11(11)e0165036
[http://dx.doi.org/10.1371/journal.pone.0165036] [PMID: 27814369]
[45]
Awad AI, Alsaleh FM. 10-year risk estimation for type 2 diabetes mellitus and coronary heart disease in Kuwait: a cross-sectional population-based study. PLoS One 2015; 10(1)e0116742
[http://dx.doi.org/10.1371/journal.pone.0116742] [PMID: 25629920]
[46]
Albayrak S, Ozhan H, Aslantas Y, Ekinozu I, Tibilli H, Kayapinar O. Melen Study Investigators. Predictors of major adverse cardiovascular events; results of population based MELEN study with prospective follow-up. Eur Rev Med Pharmacol Sci 2015; 19(8): 1446-51.
[PMID: 25967720]
[47]
Ghoreishian H, Tohidi M, Derakhshan A, et al. Presence of hypertension modifies the impact of insulin resistance on incident cardiovascular disease in a Middle Eastern population: the Tehran lipid and glucose study. Diabet Med 2015; 32(10): 1311-8.
[http://dx.doi.org/10.1111/dme.12733] [PMID: 25711172]
[48]
Lotfaliany M, Akbarpour S, Mozafary A, Boloukat RR, Azizi F, Hadaegh F. Hypertension phenotypes and incident cardiovascular disease and mortality events in a decade follow-up of a Middle East cohort. J Hypertens 2015; 33(6): 1153-61.
[http://dx.doi.org/10.1097/HJH.0000000000000540] [PMID: 25699976]
[49]
Hashemi Nazari SS, Shakiba M, Khalili D, Hadaegh F, Tohidi M, Azizi F. High-density lipoprotein cholesterol, a protective or a risk factor for developing coronary heart disease? Tehran Lipid and Glucose Study. J Clin Lipidol 2015; 9(4): 553-8.
[http://dx.doi.org/10.1016/j.jacl.2015.04.001] [PMID: 26228673]
[50]
Alsheikh-Ali AA, Omar MI, Raal FJ, et al. Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East cardiovascular epidemiological (ACE) study. PLoS One 2014; 9(8)e102830
[http://dx.doi.org/10.1371/journal.pone.0102830] [PMID: 25090638]
[51]
Amin TT, Al Sultan AI, Mostafa OA, Darwish AA, Al-Naboli MR. Profile of non-communicable disease risk factors among employees at a Saudi university. Asian Pac J Cancer Prev 2014; 15(18): 7897-907.
[http://dx.doi.org/10.7314/APJCP.2014.15.18.7897] [PMID: 25292084]
[52]
Azimi SS, Khalili D, Hadaegh F, Yavari P, Mehrabi Y, Azizi F. Calculating population attributable fraction for cardiovascular risk factors using different methods in a population based cohort study. J Res Health Sci 2015; 15(1): 22-7.
[PMID: 25821021]
[53]
Esteghamati A, Hafezi-Nejad N, Sheikhbahaei S, et al. Risk of coronary heart disease associated with metabolic syndrome and its individual components in Iranian subjects: a matched cohort study. J Clin Lipidol 2014; 8(3): 279-86.
[http://dx.doi.org/10.1016/j.jacl.2014.02.002] [PMID: 24793349]
[54]
Hajian-Tilaki K, Heidari B, Firouzjahi A, Bagherzadeh M, Hajian-Tilaki A, Halalkhor S. Prevalence of metabolic syndrome and the association with socio-demographic characteristics and physical activity in urban population of Iranian adults: a population-based study. Diabetes Metab Syndr 2014; 8(3): 170-6.
[http://dx.doi.org/10.1016/j.dsx.2014.04.012] [PMID: 25220921]
[55]
Ostovaneh MR, Zamani F, Sharafkhah M, et al. Prevalence of metabolic syndrome in Amol and Zahedan, Iran: a population based study. Arch Iran Med 2014; 17(7): 477-82.
[PMID: 24979559]
[56]
Shafiee G, Sharifi F, Alizadeh M, et al. Electrocardiogram abnormalities and risk of cardiovascular mortality and all-cause mortality in old age: the Kahrizak Elderly Study (KES). Arch Gerontol Geriatr 2014; 59(1): 69-73.
[http://dx.doi.org/10.1016/j.archger.2014.03.011] [PMID: 24794877]
[57]
Yamout R, Adib SM, Hamadeh R, Freidi A, Ammar W. Screening for cardiovascular risk in asymptomatic users of the primary health care network in Lebanon, 2012-2013. Prev Chronic Dis 2014; 11E120
[http://dx.doi.org/10.5888/pcd11.140089] [PMID: 25032835]
[58]
Aghaei Meybodi HR, Khashayar P, Rezai Homami M, Heshmat R, Larijani B. Prevalence of hypertension in an Iranian population. Ren Fail 2014; 36(1): 87-91.
[http://dx.doi.org/10.3109/0886022X.2013.832315] [PMID: 24028502]
[59]
Suleiman AK. Risk factors on hypertensive disorders among Jordanian pregnant women. Glob J Health Sci 2013; 6(2): 138-44.
[http://dx.doi.org/10.5539/gjhs.v6n2p138] [PMID: 24576373]
[60]
Ehteshami-Afshar S, Momenan A, Hajshekholeslami F, Azizi F, Hadaegh F. The impact of smoking status on 9.3 years incidence of cardiovascular and all-cause mortality among Iranian men. Ann Hum Biol 2014; 41(3): 249-54.
[http://dx.doi.org/10.3109/03014460.2013.853834] [PMID: 24215537]
[61]
Saeed AA, Al-Hamdan NA. Anthropometric risk factors and predictors of hypertension among Saudi adult population - a national survey. J Epidemiol Glob Health 2013; 3(4): 197-204.
[http://dx.doi.org/10.1016/j.jegh.2013.08.004] [PMID: 24206791]
[62]
Whitford DL, Al-Anjawi HA, Al-Baharna MM. Impact of clinical inertia on cardiovascular risk factors in patients with diabetes. Prim Care Diabetes 2014; 8(2): 133-8.
[http://dx.doi.org/10.1016/j.pcd.2013.10.007] [PMID: 24275104]
[63]
Moradi-Lakeh M, Forouzanfar MH, El Bcheraoui C, et al. Global Burden of Disease Collaborators on Eastern Mediterranean Region and Diabetes. High fasting plasma glucose, diabetes, and its risk factors in the eastern Mediterranean region, 1990-2013: findings from the global burden of disease study 2013. Diabetes Care 2017; 40(1): 22-9.
[http://dx.doi.org/10.2337/dc16-1075] [PMID: 27797926]
[64]
Benziger CP, Roth GA, Moran AE. The global burden of disease study and the preventable burden of NCD. Glob Heart 2016; 11(4): 393-7.
[http://dx.doi.org/10.1016/j.gheart.2016.10.024] [PMID: 27938824]
[65]
Raal FJ, Alsheikh-Ali AA, Omar MI, et al. Cardiovascular risk factor burden in Africa and the Middle East across country income categories: a post hoc analysis of the cross-sectional Africa Middle East Cardiovascular Epidemiological (ACE) study. Arch Public Health 2018; 76: 15.
[http://dx.doi.org/10.1186/s13690-018-0257-5] [PMID: 29449941]
[66]
Turk-Adawi K, Sarrafzadegan N, Fadhil I, et al. Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden. Nat Rev Cardiol 2018; 15(2): 106-19.
[http://dx.doi.org/10.1038/nrcardio.2017.138] [PMID: 28933782]
[67]
GBD 2015 Eastern Mediterranean region cardiovascular disease collaborations. Burden of cardiovascular disease in the Eastern Mediterranean region, 1990-2015. Findings from the Global burden of disease 2015 study. Int J Public Health 2018; 63(Suppl. 1): 137-49.
[68]
Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA 2017; 317(2): 165-82.
[http://dx.doi.org/10.1001/jama.2016.19043] [PMID: 28097354]
[69]
Aljefree N, Ahmed F. Association between dietary pattern and risk of cardiovascular disease among adults in the Middle East and North Africa region: a systematic review. Food Nutr Res 2015; 59: 27486.
[http://dx.doi.org/10.3402/fnr.v59.27486] [PMID: 26088003]
[70]
Steinhagen-Thiessen E, Bramlage P, Lösch C, et al. Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German metabolic and cardiovascular risk project (GEMCAS). Cardiovasc Diabetol 2008; 7: 31.
[http://dx.doi.org/10.1186/1475-2840-7-31] [PMID: 18922160]
[71]
Simão AF, Précoma DB, Andrade JP, Correa Filho H, Saraiva JF, Oliveira GM. Cardiovascular prevention guideline of the Brazilian Society of Cardiology - executive summary. Arq Bras Cardiol 2014; 102(5): 420-31.
[http://dx.doi.org/10.5935/abc.20140067] [PMID: 24918910]
[72]
Bays HE, Chapman RH, Fox KM, Grandy S. SHIELD Study Group. Comparison of self-reported survey (SHIELD) versus NHANES data in estimating prevalence of dyslipidemia. Curr Med Res Opin 2008; 24(4): 1179-86.
[http://dx.doi.org/10.1185/030079908X280527] [PMID: 18346311]
[73]
Joffres M, Shields M, Tremblay MS, Connor Gorber S. Dyslipidemia prevalence, treatment, control, and awareness in the Canadian Health Measures Survey. Can J Public Health 2013; 104(3): e252-7.
[http://dx.doi.org/10.17269/cjph.104.3783] [PMID: 23823891]
[74]
Al Rasadi K, Almahmeed W, AlHabib KF, et al. Dyslipidaemia in the Middle East: Current status and a call for action. Atherosclerosis 2016; 252: 182-7.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.07.925] [PMID: 27522462]
[75]
Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128: 40-50.
[http://dx.doi.org/10.1016/j.diabres.2017.03.024] [PMID: 28437734]
[76]
Majeed A, El-Sayed AA, Khoja T, Alshamsan R, Millett C, Rawaf S. Diabetes in the Middle-East and North Africa: an update. Diabetes Res Clin Pract 2014; 103(2): 218-22.
[http://dx.doi.org/10.1016/j.diabres.2013.11.008] [PMID: 24300017]
[77]
Dugani SB, Murad W, Damilig K, et al. Premature myocardial infarction in the Middle East and North Africa: rationale for the gulf prevent study. Angiology 2020; 71(1): 17-26.
[http://dx.doi.org/10.1177/0003319719849737] [PMID: 31129986]

Rights & Permissions Print Cite
Article Metrics
23
1
© 2024 Bentham Science Publishers | Privacy Policy